Efficacy of long-term (104-week) treatment with apremilast in patients with psoriatic arthritis: Results from a phase III, randomized, controlled trial and open-label extension

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase Iii ◽

Open Label ◽

Randomized Controlled ◽

THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3)

10.1136/annrheumdis-2015-eular.2889 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 348.2-349 ◽

Cited By ~ 3

Author(s):

C. Edwards ◽

F. Blanco ◽

J. Crowley ◽

C. Hu ◽

K. Shah ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase Iii ◽

Open Label ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Open Label Extension ◽

FRI0447 Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from A Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 1)

10.1136/annrheumdis-2016-eular.3256 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 597.2-598

Author(s):

A. Kavanaugh ◽

D.D. Gladman ◽

J.J. Gomez-Reino ◽

S. Hall ◽

E. Lespessailles ◽

...

Keyword(s):

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Open Label Extension ◽

217. Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)

Rheumatology ◽

10.1093/rheumatology/kev089.104 ◽

2015 ◽

Keyword(s):

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Open Label Extension ◽

SAT0562 Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4)

10.1136/annrheumdis-2015-eular.2896 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 863.2-864 ◽

Cited By ~ 5

Author(s):

A. Wells ◽

C. Edwards ◽

A. Adebajo ◽

A. Kivitz ◽

P. Bird ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients with Dementia with Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial

American Journal of Geriatric Psychiatry ◽

10.1016/j.jagp.2021.07.002 ◽

2021 ◽

Author(s):

Toshinari Odawara ◽

Kazuko Hasegawa ◽

Ritsuko Kajiwara ◽

Hisao Takeuchi ◽

Masaaki Tagawa ◽

...

Keyword(s):

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

103. Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study

Rheumatology ◽

10.1093/rheumatology/keu101.024 ◽

2014 ◽

Vol 53 (suppl_1) ◽

pp. i96-i96 ◽

Cited By ~ 1

Author(s):

Edward Keystone ◽

Robert Landewé ◽

Ronald van Vollenhoven ◽

Bernard Combe ◽

Vibeke Strand ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Controlled Trial ◽

Certolizumab Pegol ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Randomized Controlled ◽

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial

American Journal of Respiratory and Critical Care Medicine ◽

10.1164/rccm.202103-0714oc ◽

2021 ◽

Author(s):

Dinesh Khanna ◽

Celia J. F. Lin ◽

Daniel E Furst ◽

Bridget Wagner ◽

Mauro Zucchetto ◽

...

Keyword(s):

Systemic Sclerosis ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Safety And Efficacy ◽

Randomized Controlled ◽

Open Label Extension ◽

Early Systemic Sclerosis

THU0420 Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomised, Controlled Trial and Open-Label Extension (Palace 1)

10.1136/annrheumdis-2015-eular.2907 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 350.2-351 ◽

Cited By ~ 2

Author(s):

A. Kavanaugh ◽

A. Adebajo ◽

D. Gladman ◽

J. Gomez-Reino ◽

S. Hall ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Phosphodiesterase 4 ◽

Open Label Extension ◽

Randomised Controlled ◽

Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial

Epilepsy Research ◽

10.1016/j.eplepsyres.2021.106705 ◽

2021 ◽

pp. 106705

Author(s):

Yushi Inoue ◽

Weiping Liao ◽

Xuefeng Wang ◽

Xinlu Du ◽

Frank Tennigkeit ◽

...

Keyword(s):

Controlled Trial ◽

Open Label ◽

Safety And Efficacy ◽

Randomized Controlled ◽

Focal Seizures ◽

Japanese Adults ◽

Invited Perspective on the “Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients with Dementia with Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial"

American Journal of Geriatric Psychiatry ◽

10.1016/j.jagp.2021.07.017 ◽

2021 ◽

Author(s):

Jared T. Hinkle ◽

Gregory M. Pontone

Keyword(s):

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽